Assessment of glial activation response in the progress of natural scrapie after chronic dexamethasone treatment

dc.contributor.authorGuijarro, Isabel M.
dc.contributor.authorGarcés Crespo, Miguel
dc.contributor.authorAndrés Benito, Pol
dc.contributor.authorMarín, Belén
dc.contributor.authorOtero, Alicia
dc.contributor.authorBarrio Castro, Tomás del
dc.contributor.authorCarmona Murillo, Margarita
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)
dc.contributor.authorBadiola, Juan J.
dc.contributor.authorMonzón, Marta
dc.date.accessioned2020-12-11T14:26:29Z
dc.date.available2020-12-11T14:26:29Z
dc.date.issued2020-05-02
dc.date.updated2020-12-11T14:26:29Z
dc.description.abstractNeuroinflammation has been correlated with the progress of neurodegeneration in many neuropathologies. Although glial cells have traditionally been considered to be protective, the concept of them as neurotoxic cells has recently emerged. Thus, a major unsolved question is the exact role of astroglia and microglia in neurodegenerative disorders. On the other hand, it is well known that glucocorticoids are the first choice to regulate inflammation and, consequently, neuroglial inflammatory activity. The objective of this study was to determine how chronic dexamethasone treatment influences the host immune response and to characterize the beneficial or detrimental role of glial cells. To date, this has not been examined using a natural neurodegenerative model of scrapie. With this aim, immunohistochemical expression of glial markers, prion protein accumulation, histopathological lesions and clinical evolution were compared with those in a control group. The results demonstrated how the complex interaction between glial populations failed to compensate for brain damage in natural conditions, emphasizing the need for using natural models. Additionally, the data showed that modulation of neuroinflammation by anti-inflammatory drugs might become a research focus as a potential therapeutic target for prion diseases, similar to that considered previously for other neurodegenerative disorders classified as prion-like diseases.
dc.format.extent24 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701932
dc.identifier.issn1661-6596
dc.identifier.pmid32370224
dc.identifier.urihttps://hdl.handle.net/2445/172683
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms21093231
dc.relation.ispartofInternational Journal of Molecular Sciences, 2020, vol. 21, num. 9, p. 3231
dc.relation.urihttps://doi.org/10.3390/ijms21093231
dc.rightscc-by (c) Guijarro, Isabel M. et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationAstròcits
dc.subject.classificationMicròglia
dc.subject.classificationInflamació
dc.subject.classificationMalalties per prions
dc.subject.classificationTremolor ovina
dc.subject.otherAstrocytes
dc.subject.otherMicroglia
dc.subject.otherInflammation
dc.subject.otherPrion diseases
dc.subject.otherScrapie
dc.titleAssessment of glial activation response in the progress of natural scrapie after chronic dexamethasone treatment
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
701932.pdf
Mida:
4.47 MB
Format:
Adobe Portable Document Format